Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Sports
Taiwanese firefighters make history at World Police & Fire Games in U.S.
07/02/2025 08:03 PM - Society
Taiwan reports 1st imported case of P. knowlesi malaria in 20 years
07/02/2025 07:50 PM - Business
Cabinet official confident in economic outlook amid U.S. tariff concerns
07/02/2025 06:54 PM - Business
Tainan exports 5 tons of Taiwan tilapia to Singapore
07/02/2025 06:08 PM - Business
Taiwan shares edge up after recovering from earlier losses
07/02/2025 04:52 PM